Medical Editor: John P. Cunha, DO, FACOEP Last updated on RxList: 5/5/2022
Odomzo Side Effects Center

What Is Odomzo?

Odomzo (sonidegib) is a hedgehog pathway inhibitor indicated for the treatment of adult patients with locally advanced basal cell carcinoma (BCC) that has recurred following surgery or radiation therapy, or those who are not candidates for surgery or radiation therapy.

What Are Side Effects of Odomzo?

Common side effects of Odomzo include:

Dosage for Odomzo

The recommended dose of Odomzo is 200 mg orally once daily taken on an empty stomach, at least 1 hour before or 2 hours after a meal.

What Drugs, Substances, or Supplements Interact with Odomzo?

Odomzo may interact with saquinavir, telithromycin, azole antifungals, nefazodone, atanzavir, diltiazem, carbamazepine, efavirenz, modafinil, phenobarbital, phenytoin, rifabutin, rifampin, and St. John's Wort. Tell your doctor all medications and supplements you use.

Odomzo During Pregnancy or Breastfeeding

Odomzo is not recommended for use during pregnancy. It may harm a fetus. Women should use effective contraception during treatment with Odomzo and for at least 20 months after the last dose. Men should use condoms, even after a vasectomy, to avoid potential drug exposure to pregnant partners and female partners of reproductive potential during treatment with Odomzo and for at least 8 months after the last dose. Breastfeeding is not recommended while using Odomzo and for at least 20 months after the last dose.

Additional Information

Our Odomzo (sonidegib) Side Effects Drug Center provides a comprehensive view of available drug information on the potential side effects when taking this medication.

This is not a complete list of side effects and others may occur. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.


Self-examination is important in the detection of skin cancer. See Answer
Odomzo Consumer Information

Get emergency medical help if you have signs of an allergic reaction: hives; difficult breathing; swelling of your face, lips, tongue, or throat.

Sonidegib can cause a condition that results in the breakdown of skeletal muscle tissue, leading to kidney failure. Call your doctor right away if you have:

  • severe or unexplained muscle pain or weakness (even if this occurs after you have stopped taking sonidegib);
  • little or no urinating; or
  • dark colored urine.

Common side effects may include:

  • stomach pain, nausea, vomiting, diarrhea;
  • loss of appetite, weight loss;
  • tiredness;
  • itchy skin, hair loss; or
  • changes in your sense of taste.

This is not a complete list of side effects and others may occur. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.

Read the entire detailed patient monograph for Odomzo (Sonidegib Capsules)


Sun-Damaged Skin: Pictures of Sun Spots, Wrinkles, Sunburns See Slideshow
Odomzo Professional Information


The following clinically significant adverse reactions are described elsewhere in the labeling:

  • Musculoskeletal Adverse Reactions [see WARNINGS AND PRECAUTIONS].

Clinical Trials Experience

Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in clinical practice.

The safety of ODOMZO was evaluated in BOLT, a randomized, double-blind, multiple cohort trial in which 229 patients received ODOMZO at either 200 mg (n=79) or 800 mg (n=150) daily. The frequency of common adverse reactions including muscle spasms, alopecia, dysgeusia, fatigue, nausea, decreased weight, decreased appetite, myalgia, pain, and vomiting was greater in patients treated with ODOMZO 800 mg as compared to 200 mg.

The data described below reflect exposure to ODOMZO 200 mg daily in 79 patients with locally advanced BCC (laBCC; n=66) or metastatic BCC (mBCC; n=13) enrolled in Study 1. Patients were followed for at least 18 months unless discontinued earlier. The median duration of treatment with ODOMZO was 11.0 months (range 1.3 to 33.5 months).

The study population characteristics were: median age of 67 years (range 25 to 92; 59% were ≥65 years), 61% male, and 90% white. The majority of patients had prior surgery (75%), radiotherapy (24%), systemic chemotherapy (4%), or topical or photodynamic therapies (18%) for treatment of BCC. No patient had prior exposure to a Hh pathway inhibitor.

ODOMZO was permanently discontinued in 34% of patients or temporarily interrupted in 20% of patients for adverse reactions. Adverse reactions reported in at least two patients that led to discontinuation of the drug were: muscle spasms, and dysgeusia (each 5%), asthenia, increased lipase, and nausea (each 4%), fatigue, decreased appetite, alopecia, and decreased weight (each 3%). Serious adverse reactions occurred in 18% of patients.

The most common adverse reactions occurring in ≥10% of patients treated with ODOMZO 200 mg were muscle spasms, alopecia, dysgeusia, fatigue, nausea, musculoskeletal pain, diarrhea, decreased weight, decreased appetite, myalgia, abdominal pain, headache, pain, vomiting, and pruritus (Table 1).

The key laboratory abnormalities are described in Table 2.

Table 1: Adverse Reactions Occurring in ≥10% of Patients in BOLT

Adverse Reaction ODOMZO 200 mg
All Gradesa
Grade 3
Musculoskeletal and connective tissue
  Muscle spasms 54 3
  Musculoskeletal pain 32 1
  Myalgia 19 0
Skin and subcutaneous tissue
  Alopecia 53 0
  Pruritus 10 0
Nervous system
  Dysgeusia 46 0
  Headache 15 1
  Fatigue 41 4
  Pain 14 1
  Nausea 39 1
  Diarrhea 32 1
  Abdominal pain 18 0
  Vomiting 11 1
  Decreased weight 30 3
Metabolism and nutrition
  Decreased appetite 23 1
a No Grade 4 adverse reactions were reported.

Table 2: Key Laboratory Abnormalitiesa in BOLT

Laboratory Test ODOMZO 200 mg
All Grades
Grades 3-4
  Increased serum creatinine 92b 0
  Increased serum creatine kinase (CK) 61 8
  Hyperglycemia 51 4
  Increased lipase 43 13
  Increased alanine aminotransferase 19 4
  Increased aspartate aminotransferase 19 4
  Increased amylase 16 1
  Anemia 32 0
  Lymphopenia 28 3
a Based on worst post-treatment laboratory value regardless of baseline; grading by CTCAE v4.03.
b The serum creatinine level remained within normal range in 76% (60/79) of patients.


Amenorrhea lasting for at least 18 months occurred in two of 14 pre-menopausal women treated with ODOMZO 200 mg or 800 mg once daily.

Read the entire FDA prescribing information for Odomzo (Sonidegib Capsules)

© Odomzo Patient Information is supplied by Cerner Multum, Inc. and Odomzo Consumer information is supplied by First Databank, Inc., used under license and subject to their respective copyrights.

Health Solutions From Our Sponsors